Press release
Breast Cancer Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024
Breast Cancer Pipeline
Key Takeaways from the Breast Cancer Pipeline Report
• DelveInsight's Breast Cancer pipeline report depicts a robust space with 120+ Breast Cancer companies working to develop 130+ pipeline therapies for Breast Cancer treatment.
• The leading Breast Cancer Companies working in the market include Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others.
• Promising Breast Cancer Pipeline Therapies in the various stages of development includes Oraxol, ARV-471, Ribociclib, E7389, Trastuzumab, GM-CSF, GM-CSF, Trastuzumab, Paclitaxel, Gemcitabine/Carboplatin, Iniparib, and others.
• December 2023: Cancer Insight LLC announced a study of Phase 2 clinical trials for Trastuzumab and GM-CSF. In this study, the investigators intend to assess the ability of the combination of trastuzumab and the HER2 vaccine nelipepimut-S (administered with the immunoadjuvant GM-CSF) given in the adjuvant setting to prevent recurrences in patients with high-risk HER2-positive breast cancer. High-risk is defined as those patients that do not achieve a pCR after neoadjuvant therapy with an approved regimen that includes trastuzumab and at least four cycles (12 weeks) of taxane-containing chemotherapy or those who undergo upfront surgery and are found to have greater than or equal to four positive lymph nodes regardless of hormone receptor status or 1-3 positive lymph nodes and are hormone receptor negative.
• December 2023: Seagen Inc. announced a study of Phase 3 clinical trials for Tucatinib, Trastuzumab and Pertuzumab. This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast cancer. A placebo is a pill that looks the same as tucatinib but has no medicine in it. This study will also test what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease.
• December 2023: AstraZeneca announced a study of Phase 3 clinical trials for Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin and Cyclophosphamide. This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer.
Request a sample and discover the recent advances in Breast Cancer Treatment Drugs @ Breast Cancer Pipeline Outlook Report- https://www.delveinsight.com/report-store/breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
The Breast Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Breast Cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Breast Cancer clinical trial landscape.
Breast Cancer Overview
Breast cancer is the most common cancer diagnosed in women, accounting for more than 1 in 10 new cancer diagnoses each year. It is the second most common cause of death from cancer among women in the world. Anatomically, the breast has milk-producing glands in front of the chest wall. They lie on the pectoralis major muscle, and there are ligaments support the breast and attach it to the chest wall. Fifteen to 20 lobes circularly arranged to form the breast.
Find out more about Breast Cancer Treatment Landscape @ Drugs for Breast Cancer Treatment- https://www.delveinsight.com/sample-request/breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Breast Cancer Emerging Drugs Profile
• SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
• HLX11: Shanghai Henlius Biotech
• Praluzatamab ravtansine: CytomX Therapeutics
• MCLA-128: Merus N.V.
• DX126 262: Hangzhou DAC Biotech
Breast Cancer Pipeline Therapeutics Assessment
There are approx. 120+ key Breast Cancer companies which are developing the Breast Cancer therapies. The Breast Cancer companies which have their Breast Cancer drug candidates in the most advanced stage, i.e. phase III include, Jiangsu HengRui Medicine Co., Ltd.
DelveInsight's Breast Cancer pipeline report covers around 130+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Breast Cancer Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Learn more about the emerging Breast Cancer Pipeline Therapies @ Breast Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Breast Cancer Pipeline Report
• Coverage- Global
• Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Breast Cancer Companies- Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others.
• Breast Cancer Pipeline Therapies- Oraxol, ARV-471, Ribociclib, E7389, Trastuzumab, GM-CSF, GM-CSF, Trastuzumab, Paclitaxel, Gemcitabine/Carboplatin, Iniparib, and others.
Dive deep into rich insights for new drugs for Breast Cancer treatment, Visit @ Breast Cancer Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Breast Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Breast Cancer- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. MCLA-128: Merus N.V.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. DX126 262: Hangzhou DAC Biotech
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. ES2B C001: ExpreS2ion Biotechnologies
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Breast Cancer Companies
21. Breast Cancer Products
22. Breast Cancer Unmet Needs
23. Breast Cancer Market Drivers and Barriers
24. Breast Cancer Future Perspectives and Conclusion
25. Breast Cancer Analyst Views
26. Breast Cancer Companies
27. Appendix
For further information on the Breast Cancer pipeline therapeutics, reach out to Breast Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Important Links-
https://germanydennydones.bloggip.com/profile
https://germanydennydones.creacionblog.com/profile
https://germanydennydones.dm-blog.com/profile
https://germanydennydones.tusblogos.com/profile
https://germanydennydones.spintheblog.com/profile
https://germanydennydones.dailyblogzz.com/profile
https://germanydennydones.bloginder.com/profile
https://germanydennydones.blogvivi.com/profile
https://germanydennydones.bleepblogs.com/profile
https://germanydennydones.get-blogging.com/profile
https://germanydennydones.targetblogs.com/profile
https://germanydennydones.newsbloger.com/profile
https://germanydennydones.blogdal.com/profile
https://germanydennydones.ja-blog.com/profile
https://germanydennydones.blogscribble.com/profile
https://germanydennydones.madmouseblog.com/profile
https://germanydennydones.activoblog.com/profile
https://germanydennydones.blog-ezine.com/profile
https://germanydennydones.blogtov.com/profile
https://germanydennydones.digitollblog.com/profile
https://germanydennydones.blazingblog.com/profile
https://germanydennydones.smblogsites.com/profile
https://germanydennydonesc.weblogco.com/profile
https://germanydennydones.blogdeazar.com/profile
https://germanydennydones.eedblog.com/profile
https://germanydennydones.theisblog.com/profile
https://germanydennydones.blog2freedom.com/profile
https://germanydennydones.qodsblog.com/profile
https://germanydennydones.bloggazza.com/profile
https://germanydennydones.bloggactivo.com/profile
https://germanydennydones.bloggadores.com/profile
https://germanydennydones.blogsvirals.com/profile
https://germanydennydones.blog-gold.com/profile
https://germanydennydones.ambien-blog.com/profile
https://germanydennydones.atualblog.com/profile
https://germanydennydones.blog-a-story.com/profile
https://germanydennydones.blogacep.com/profile
https://germanydennydones.blogadvize.com/profile
https://germanydennydones.bloggerbags.com/profile
https://germanydennydones.bloggerswise.com/profile
https://germanydennydones.bloggosite.com/profile
https://germanydennydones.blogoscience.com/profile
https://germanydennydones.blogproducer.com/profile
https://germanydennydones.blogrelation.com/profile
https://germanydennydones.blogrenanda.com/profile
https://germanydennydones.blogsidea.com/profile
https://germanydennydones.blogthisbiz.com/profile
https://germanydennydones.blue-blogs.com/profile
https://germanydennydones.csublogs.com/profile
https://germanydennydones.dailyhitblog.com/profile
https://germanydennydones.develop-blog.com/profile
https://germanydennydones.livebloggs.com/profile
https://germanydennydones.is-blog.com/profile
https://hyperbookmarks.com/story16829911/atopic-dermatitis-market-size
https://hotbookmarkings.com/story16883941/atopic-dermatitis-market-outlook
https://extrabookmarking.com/story16805585/atopic-dermatitis-market-forecast
https://enrollbookmarks.com/story16793892/atopic-dermatitis-market-trends
https://digibookmarks.com/story16832272/atopic-dermatitis-treatment-market
https://bookmarktune.com/story16785555/atopic-dermatitis-market-insights
https://bookmarkpressure.com/story16812823/atopic-dermatitis-market
https://bookmarkjourney.com/story16864476/atopic-dermatitis-market-size
https://bookmarkindexing.com/story16742365/atopic-dermatitis-market-outlook
https://maximusbookmarks.com/story16970425/atopic-dermatitis-market-forecast
https://bookmarkforest.com/story16794298/atopic-dermatitis-drug-market
https://bookmarkchamp.com/story16807071/atopic-dermatitis-drug-market
https://bookmarkingquest.com/story16806001/atopic-dermatitis-drug-market
https://bookmarkingbay.com/story16763993/atopic-dermatitis-drug-market
https://active-bookmarks.com/story16761273/atopic-dermatitis-market-forecast
https://dmozbookmark.com/story16828056/atopic-dermatitis-drug-market
https://bookmarklinx.com/story16889261/atopic-dermatitis-market-outlook
https://bookmarkerz.com/story16762032/atopic-dermatitis-market-size
https://bookmarkahref.com/story16846516/atopic-dermatitis-drug-market
https://top10bookmark.com/story16738693/atopic-dermatitis-market-size
https://tinybookmarks.com/story16871257/atopic-dermatitis-market-outlook
https://thebookmarknight.com/story16844966/atopic-dermatitis-market-trends
https://scrapbookmarket.com/story16804746/atopic-dermatitis-market-share
https://royalbookmarking.com/story16846844/atopic-dermatitis-drug-market
https://nanobookmarking.com/story16794126/atopic-dermatitis-treatment-market-size
https://modernbookmarks.com/story16676860/atopic-dermatitis-treatment-market
https://listingbookmarks.com/story16875255/atopic-dermatitis-market-trends
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/vulvar-cancer-market
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Breast Cancer Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 here
News-ID: 3434958 • Views: …
More Releases from DelveInsight Business Research LLP
Alpha-1 Protease Inhibitor Deficiency Market Size 2032: CSL Behring, Grifols The …
DelveInsight's "Alpha-1 Protease Inhibitor Deficiency Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Alpha-1 Protease Inhibitor Deficiency, historical and forecasted epidemiology as well as the Alpha-1 Protease Inhibitor Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Alpha-1 Protease Inhibitor Deficiency Market Research Report
• The increase in Alpha-1 Protease Inhibitor Deficiency Market Size…
Amyloidosis Market Size Report 2032: Attralus Inc., Novotech Pty Limited, Criter …
DelveInsight's "Amyloidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Amyloidosis, historical and forecasted epidemiology as well as the Amyloidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Amyloidosis Market Research Report
• The increase in Amyloidosis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies…
Basal Cell Nevus Syndrome Market Size Report 2032: Latest FDA Approvals, Emergin …
DelveInsight's "Basal Cell Nevus Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Nevus Syndrome, historical and forecasted epidemiology as well as the Basal Cell Nevus Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Basal Cell Nevus Syndrome Market Research Report
• The increase in Basal Cell Nevus Syndrome Market Size…
Biliary Atresia Market Size Report 2032: Latest FDA Approvlas and Pipeline Repor …
DelveInsight's "Biliary Atresia Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology as well as the Biliary Atresia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Key Takeaways from the Biliary Atresia Market Research Report
• The increase in Biliary Atresia Market Size is a direct consequence of the increasing…
More Releases for Breast
Breast Ultrasound Market Research Report and Forecast to 2028 - Conventional Bre …
A breast ultrasound is an imaging method chiefly utilized to screen for tumours and other breast abnormalities. The ultrasound use high-frequency sound waves for the production of detailed images of the inside of the breasts.
The global Breast Ultrasound Market is expected to grow at a significant CAGR of 14.6% by 2028.
The updated report on the Breast Ultrasound market gives a precise analysis of the value chain assessment for the review…
Breast Imaging Market by Breast Ultrasound, Breast MRI, Automated Whole-Breast U …
Growth of breast imaging market driven by factors like rising incidence of breast cancer globally, growing government investments and funding for breast cancer treatment and related research, increasing awareness about early detection of breast cancer, rising geriatric population, technological advancements in breast imaging modalities, and launch of advanced breast imaging systems capable of detecting cancer in women with dense breast tissues.
Download Free PDF Brochure on Brest Imaging Market Report Now…
Breast Implants Market Report 2018: Segmentation by Product (Silicone Breast Imp …
Global Breast Implants market research report provides company profile for Allergan, Mentor Worldwide LLC, Hans biomed, Establishment Labs, Polytech Health & Aesthetics, Sientra, Inc., GC Aesthetics, Cereplas and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to…
Automated Breast Ultrasound Systems – The Future of Breast Screening
Breast cancer is the most commonly diagnosed type of cancer and the second leading cause of death among women, as evident from stats revealed by the National Breast Cancer Foundation. Growing awareness of breast cancer has increased number of women undergoing breast screening and in turn would propel demand for automated breast ultrasound systems (ABUS) in hospitals and diagnostic centers. ABUS enables physicians to screen women, especially with denser breasts…
Soaring Instances of Breast Cancer to Propel Breast Imaging Market
"The Report Breast Imaging Market (Mammography, Breast MRI, Breast Ultrasound, Tomosynthesis, Nuclear Imaging and Others [Breast Thermography & Bioelectric Imaging]) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
An intelligence report on the global breast imaging market has been added to the burgeoning portfolio of MarketResearchReports.biz. Titled, “Breast Imaging…
What Is A Combined Breast Augmentation With Breast Lift?
Combined Breast Augmentation And Lift: How Is It Performed?
Surrounding the areola one incisions is made to remove the excess skin and another vertically incisions is made to the base of breasts starting from low part of the areola. Sometimes the scar is referred to as the “Lollipop scar”. Implants are placed through the incisions made and positioned carefully by the surgeon under the pectoral chest muscle, where the implants can…
